Technology
Autoimmunity BioSolutions
Upcoming May 27, 2026
An immuno-corrective approach for the 25 million people with autoimmune diseases who currently don’t respond to treatment
An immuno-corrective approach for the 25 million people with autoimmune diseases who currently don’t respond to treatment
Oban BioPharma is developing a novel oral treatment class for Type 2 diabetes and obesity that works across multiple pathways involved in metabolism at once
Cycurion delivers a fully cloud-native, hardware-free security architecture that detects, mitigates, and neutralizes threats in real time
Ticonderoga Strategic Event Fund focuses event-driven opportunities and mispriced situations created by today’s improving M&A landscape
Ticonderoga Strategic Event Fund focuses event-driven opportunities and mispriced situations created by today’s improving M&A landscape
Cycurion delivers a fully cloud-native, hardware-free security architecture that detects, mitigates, and neutralizes threats in real time
A revolutionary approach to treating autoimmune disease that’s rooted in precision medicine, rather than broad immunosuppression
Ultrashort pulse lasers deliver intense bursts of energy and can destroy optical and infrared sensors on drones in less than a second
Cycurion delivers a fully cloud-native, hardware-free security architecture that detects, mitigates, and neutralizes threats in real time
A revolutionary approach to treating autoimmune disease that’s rooted in precision medicine, rather than broad immunosuppression
Myris Therapeutics is revolutionizing the delivery of small molecule cancer therapies with its HiDAR Precision Medicine Platform
IQSTEL (NASDAQ: IQST) reaches over 600 telecom operators with access to approximately 2.3 billion end users around the world.